Navigation Links
Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Date:3/9/2009

EAST BRUNSWICK, N.J., March 9 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, President of Savient Pharmaceuticals will be presenting at the upcoming Cowen and Company 29th Annual Healthcare Conference.

The presentation is scheduled to begin on Tuesday, March 17, 2009 at 8:45 a.m. Eastern Time. The Conference will be held at the Boston Marriott Copley Place in Boston, MA, March 16-19, 2009.

Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' Web site, http://www.savient.com. A replay of the webcast will be available on the Company's Web site for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The Company's product development candidate, KRYSTEXXA(TM) (pegloticase) for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; the Phase 3 clinical studies were completed in October 2007; the BLA was filed with the FDA in October 2008 and the FDA granted priority review status in December 2008. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: http://www.savient.com.

SVNT-G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , ... Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System . ... , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon Goodwill Industries, ... unique opportunity that helps high school girls succeed in STEM programs as well ... Horizon Goodwill will host over 20 high school girls at their corporate headquarters ...
(Date:7/24/2017)... ... , ... Every year, thousands of dedicated Higher Education and K12 professionals flock ... coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to take ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs secured ...
(Date:7/24/2017)... ... July 24, 2017 , ... A CDC study shows that, although people are taking more ... 18 to 29), had at least one case of sunburn within the past year. It’s ... people to ignore the issue. However, only recently have people become conscientious of the risks ...
(Date:7/24/2017)... ... , ... Sharon Kleyne, host of the nationally syndicated The Sharon Kleyne Hour ... Tears® EyeMist® recently talked on the air about an alarming Post magazine article of ... Zidor Aldama described the situation in which Chinese children are under pressure to perform ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/21/2017)... -- Did you know that PhRMA member companies invested $65.5 billion ... on brand medicines, generics and the supply chain account for 14 ... half of this (7 percent)? Or that the United ... capital investments in high-growth biopharmaceutical startups? ... The biopharmaceutical industry ...
(Date:7/19/2017)...  Mako Medical Laboratories partnered with Secretary Strickland, the ... Fund (MFA) to bring 140 soldiers back home to ... families one last time before being deployed. Mako Medical ... logistics needed for these soldiers. "Mako Medical Laboratories is ... We just wish we could bring them all home," ...
Breaking Medicine Technology: